Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. It is taken by mouth or administered intravenously.
via Wikipedia infobox
{{Infobox drug | Verifiedfields = changed | verifiedrevid = 444391072 | image = Selexipag.svg | image_class = skin-invert-image | width = | alt = | caption =
| pronounce = | tradename = Uptravi | Drugs.com = | MedlinePlus = | DailyMedID = Selexipag | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth, intravenous | class = prostacyclin receptor agonist | ATC_prefix = B01 | ATC_suffix = AC27 | ATC_supplemental =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).